What’s New and Updates/Changes

Official Press Release – Developing Section on Cost-Effectiveness of Treatment
Thursday, March 12, 2015
The following statement has been released with regard to the Cost-Effectiveness of Treatment section currently in development:
Hepatitis C Guidance Website to Develop Section on Cost-Effectiveness of Treatment
HCVguidelines.org, a website developed by the American Association of the Study for Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) in collaboration with International Antiviral Society-USA (IAS-USA) to provide up-to-date guidance on the treatment of hepatitis C (HCV), will be updated with a section on cost-effectiveness of treatment. The recent availability of new, direct-acting antivirals for the treatment of hepatitis C (HCV) offers the prospect of cure for the great majority of patients with HCV. The high costs of these new therapies have been the subject of much discussion, and IDSA and AASLD are concerned that the pricing of these drugs may put such therapy out of reach for many patients in need. This new section of the guidance will examine the cost-effectiveness of treatment to help clinicians advise and educate their patients, which is the purpose of the guidance. The new section will not, however, make recommendations regarding the pricing of these therapies for the treatment of HCV. We remain hopeful that the various stakeholders can work together to maximize patient access to optimal care. The development of this cost effectiveness analysis has been initiated and the section will be released as expeditiously as feasible.
Community Representative Nominations for the HCV Guidance Panel Needed
Friday, January 9, 2015

The AASLD and IDSA in collaboration with IAS–USA HCV Guidance Panel is seeking an additional community representative to serve on the panel that drafts the Recommendations for Testing, Managing, and Treating Hepatitis C. Community representatives serve a 2 to 3 year term, similar to the scientific panel members, and are expected to serve on at least one subcommittee and to participate actively in all subcommittee and full committee teleconferences. In-person meetings are not expected to occur more than once annually. This is a volunteer position; panel members do not receive a stipend or travel expenses, although assistance with travel may be provided in appropriate circumstances.

Ideal applicants will either have had HCV infection in the past or present, or been active in community organizations representing persons with HCV infection or those at high risk for HCV infection. The chosen applicant must comply with conflict of interest standards of the panel.

Interested individuals should forward a short letter of interest, a curriculum vitae or resume, and a completed conflict of interest disclosure form to: hcvguidelines@iasusa.org by February 15, 2015. Applicants will be screened by a nomination committee and select individuals will be interviewed by phone before final decisions are made.

Unique Patient Populations: Patients With Decompensated Cirrhosis
Monday, December 29, 2014

Additional revisions have been made to Unique Patient Populations: Patients With Decompensated Cirrhosis, sharpening the focus to patients with decompensated cirrhosis only. For guidance on patients with compensated cirrhosis, please refer to Initial Treatment of HCV Infection

Guidance Sections Updated
Friday, December 19, 2014

The Initial, Retreatment, Monitoring, and Unique Populations (HIV/HCV Coinfection, Cirrhosis, Post-Liver Transplantation, and Renal Impairment) sections have been extensively revised based on newly available therapies and data.

Updated When and In Whom to Initiate Therapy
Thursday, November 20, 2014

The introductory statement of When and In Whom to Initiate Therapy has been revised to reiterate that treatment will benefit almost all patients in all stages of chronic infection and that urgent initiation of therapy is needed in patients with certain conditions.